## Hakan Widner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12074026/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine, 2008, 14, 501-503.	30.7	1,595
2	Core assessment program for intracerebral transplantations (CAPIT). Movement Disorders, 1992, 7, 2-13.	3.9	874
3	Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Movement Disorders, 1999, 14, 572-584.	3.9	724
4	Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nature Neuroscience, 1999, 2, 1137-1140.	14.8	663
5	Bilateral Fetal Mesencephalic Grafting in Two Patients with Parkinsonism Induced by 1-Methyl-4-Phenyl-L,2,3,6-Tetrahydropyridine (MPTP). New England Journal of Medicine, 1992, 327, 1556-1563.	27.0	558
6	The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurology, The, 2013, 12, 264-274.	10.2	426
7	Dyskinesias following neural transplantation in Parkinson's disease. Nature Neuroscience, 2002, 5, 627-628.	14.8	424
8	Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Annals of Neurology, 1994, 35, 172-180.	5.3	412
9	Transplantation of fetal dopamine neurons in Parkinson's disease: One-year clinical and neurophysiological observations in two patients with putaminal implants. Annals of Neurology, 1992, 31, 155-165.	5.3	359
10	Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis. Brain Research Reviews, 1988, 13, 287-324.	9.0	342
11	Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Annals of Neurology, 1997, 42, 95-107.	5.3	331
12	Transplantation of fetal dopamine neurons in Parkinson's disease: PET {18F}6-L-fluorodopa studies in two patients with putaminal implants. Annals of Neurology, 1992, 31, 166-173.	5.3	304
13	Longâ€ŧerm efficacy of thalamic deep brain stimulation for tremor: Doubleâ€blind assessments. Movement Disorders, 2003, 18, 163-170.	3.9	285
14	Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nature Medicine, 1999, 5, 97-100.	30.7	279
15	Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease. JAMA Neurology, 2014, 71, 83.	9.0	257
16	Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Annals of Neurology, 2000, 48, 689-695.	5.3	246
17	Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6544-6549.	7.1	235
18	Red flags for multiple system atrophy. Movement Disorders, 2008, 23, 1093-1099.	3.9	215

HAKAN WIDNER

#	Article	IF	CITATIONS
19	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. Movement Disorders, 2010, 25, 2604-2612.	3.9	205
20	Characterization of Lewy body pathology in 12―and 16â€yearâ€old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Movement Disorders, 2010, 25, 1091-1096.	3.9	181
21	Immune problems in central nervous system cell therapy. NeuroRx, 2004, 1, 472-481.	6.0	169
22	Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nature Medicine, 1995, 1, 226-231.	30.7	146
23	Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Brain, 2015, 138, 963-973.	7.6	140
24	In vivo retention of <sup>18</sup> F-AV-1451 in corticobasal syndrome. Neurology, 2017, 89, 845-853.	1.1	103
25	Healthâ€related quality of life in multiple system atrophy. Movement Disorders, 2006, 21, 809-815.	3.9	102
26	A Swedish family with de novo α-synuclein A53T mutation: Evidence for early cortical dysfunction. Parkinsonism and Related Disorders, 2009, 15, 627-632.	2.2	101
27	Measuring Fatigue in Parkinson's Disease: A Psychometric Study of Two Brief Generic Fatigue Questionnaires. Journal of Pain and Symptom Management, 2006, 32, 420-432.	1.2	97
28	Signs of Degeneration in 12–22-Year Old Grafts of Mesencephalic Dopamine Neurons in Patients with Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 83-92.	2.8	90
29	Clinical rating of dyskinesias in Parkinson's disease: Use and reliability of a new rating scale. Movement Disorders, 1999, 14, 448-455.	3.9	87
30	Xenotransplantation for CNS repair: immunological barriers and strategies to overcome them. Trends in Neurosciences, 2000, 23, 337-344.	8.6	70
31	Sequential Intracerebral Transplantation of Allogeneic and Syngeneic Fetal Dopamine-Rich Neuronal Tissue in Adult Rats: Will the First Graft be Rejected?. Cell Transplantation, 1993, 2, 307-317.	2.5	69
32	Intrastriatal Ventral Mesencephalic Xenografts of Porcine Tissue in Rats: Immune Responses and Functional Effects. Cell Transplantation, 2000, 9, 261-272.	2.5	63
33	Accuracy and Sensitivity of Parkinsonian Disorder Diagnoses in Two Swedish National Health Registers. Neuroepidemiology, 2012, 38, 186-193.	2.3	58
34	Porcine Neural Xenografts in Rats and Mice: Donor Tissue Development and Characteristics of Rejection. Experimental Neurology, 2001, 172, 100-114.	4.1	57
35	Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. Movement Disorders, 2016, 31, 1020-1026.	3.9	49
36	Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. Movement Disorders, 2000, 15, 224-229.	3.9	47

HAKAN WIDNER

#	Article	IF	CITATIONS
37	<sup>11</sup> Câ€PE2I and <sup>18</sup> Fâ€Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. Movement Disorders, 2018, 33, 117-127.	3.9	45
38	Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism and Related Disorders, 2016, 29, 17-23.	2.2	43
39	First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation. Parkinsonism and Related Disorders, 2012, 18, 332-338.	2.2	40
40	Proinflammatory Cytokines Are Elevated in Serum of Patients with Multiple System Atrophy. PLoS ONE, 2013, 8, e62354.	2.5	40
41	Differential effects of Bcl-2 overexpression on fibre outgrowth and survival of embryonic dopaminergic neurons in intracerebral transplants. European Journal of Neuroscience, 1999, 11, 3073-3081.	2.6	39
42	Quinolinic acid-induced inflammation in the striatum does not impair the survival of neural allografts in the rat. European Journal of Neuroscience, 1998, 10, 2595-2606.	2.6	38
43	Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. Neuroradiology, 2015, 57, 1079-1091.	2.2	37
44	Neural Tissue Xenotransplantation: What is Needed Prior to Clinical Trials in Parkinson's Disease?. Cell Transplantation, 2000, 9, 235-246.	2.5	36
45	Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease. PLoS ONE, 2016, 11, e0157755.	2.5	35
46	Human Natural Antibodies Cytotoxic to Pig Embryonic Brain Cells Recognize Novel Non-Galα1,3Gal-Based Xenoantigens. Experimental Neurology, 1999, 159, 347-361.	4.1	33
47	Clinical neurotransplantation: Core assessment protocol rather than sham surgery as control. Brain Research Bulletin, 2002, 58, 547-553.	3.0	29
48	Intracerebral cytokine profiles in adult rats grafted with neural tissue of different immunological disparity. Brain Research Bulletin, 2004, 63, 105-118.	3.0	29
49	Alpha-synuclein multiplications with parkinsonism, dementia or progressive myoclonus?. Parkinsonism and Related Disorders, 2009, 15, 390-392.	2.2	29
50	Initiation of Levodopa-Carbidopa IntestinalÂGel Infusion Using Telemedicine (Video Communication) Tj ETQq0 0 ( Disease. Journal of Parkinson's Disease, 2017, 7, 719-728.	) rgBT /O 2.8	verlock 10 Tf 29
51	Complete ascertainment of Parkinson disease in the Swedish Twin Registry. Neurobiology of Aging, 2008, 29, 1765-1773.	3.1	27
52	Methylprednisolone prevents rejection of intrastriatal grafts of xenogeneic embryonic neural tissue in adult rats. Brain Research, 1996, 712, 199-212.	2.2	26
53	Enhanced Survival of Porcine Neural Xenografts in Mice Lacking CD1d1, But No Effect of NK1.1 Depletion. Cell Transplantation, 2001, 10, 295-304.	2.5	25
54	Simultaneous inhibition of B7 and LFA-1 signaling prevents rejection of discordant neural xenografts in mice lacking CD40L. Xenotransplantation, 2002, 9, 68-76.	2.8	25

HAKAN WIDNER

#	Article	IF	CITATIONS
55	Induction of operational tolerance to discordant dopaminergic porcine xenografts1. Transplantation, 2003, 75, 1448-1454.	1.0	24
56	Alteration of putaminal fractional anisotropy in Parkinson's disease: a longitudinal diffusion kurtosis imaging study. Neuroradiology, 2018, 60, 247-254.	2.2	23
57	Rat Intrastriatal Neural Allografts Challenged with Skin Allografts at Different Time Points. Experimental Neurology, 1997, 148, 334-347.	4.1	20
58	Porcine Embryonic Brain Cell Cytotoxicity Mediated by Human Natural Killer Cells. Cell Transplantation, 1999, 8, 601-610.	2.5	20
59	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. Parkinsonism and Related Disorders, 2018, 56, 33-40.	2.2	17
60	Discordant xenografts: different outcome after mouse and rat neural tissue transplantation to guinea-pigs. Brain Research Bulletin, 1999, 49, 367-376.	3.0	12
61	Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. Parkinsonism and Related Disorders, 2019, 66, 158-165.	2.2	12
62	Expression of Platelet-Derived Growth Factor in and around Intrastriatal Embryonic Mesencephalic Grafts. Cell Transplantation, 1993, 2, 151-162.	2.5	11
63	Fulfilment of patients' goals after thalamic deep brain stimulation: A follow-up study. Parkinsonism and Related Disorders, 2007, 13, 29-34.	2.2	9
64	Activated Porcine Embryonic Brain Endothelial Cells Induce a Proliferative Human T-Lymphocyte Response. Cell Transplantation, 2003, 12, 637-646.	2.5	7
65	Chapter 8 Xenotransplantation. Progress in Brain Research, 2000, 127, 157-188.	1.4	6
66	The Lund Transplant Program for Parkinson's Disease and Patients with MPTP-Induced Parkinsonism. , 1998, , 1-17.		6
67	Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort. Journal of Parkinson's Disease, 2022, 12, 153-171.	2.8	5
68	Immunological Issues in Rodent and Primate Transplants (Allografts). , 0, , 171-188.		4
69	Strategies to modify levodopa treatment. Advances in Neurology, 2003, 91, 229-36.	0.8	4
70	Parkinson's disease laterality: a 11C-PE2I PET imaging study. Journal of Neurology, 2021, 268, 582-589.	3.6	3
71	Genetically Targeted Clinical Trials in Parkinson's Disease: Learning from the Successes Made in Oncology. Genes, 2021, 12, 1529.	2.4	2
72	Immunological Issues in Rodent and Primate Transplants (Allografts). , 1998, , 171-187.		1

0
0
0
0
0